Summary
Agilent Technologies announced a significant organizational restructuring in November 2014, the details of which are being provided in this Form 8-K filing. The company is realigning its business segments to better serve its customers, creating three new reportable segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. This change aims to streamline operations and enhance focus within these key areas. Investors should note that the provided segment information, furnished as Exhibit 99.1, is for informational purposes and is not deemed "filed" for liability purposes under SEC rules.
Key Highlights
- 1Agilent Technologies is restructuring its business into three new reportable segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab.
- 2The Life Sciences and Applied Markets segment will combine the existing life sciences business (excluding nucleic acid solutions) with the chemical analysis business.
- 3The Diagnostics and Genomics segment will merge the diagnostics and genomics businesses with the nucleic acid solutions division from the life sciences business.
- 4The Agilent CrossLab segment will be formed from the services and consumables businesses.
- 5This restructuring aims to improve customer service and operational focus.
- 6The filing includes furnished selected segment information for fiscal quarters and years ending in 2012, 2013, and 2014, reflecting these organizational changes.
- 7The information is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, limiting liability.
Frequently Asked Questions
The primary purpose of this 8-K filing is to provide investors with selected segment information that reflects changes in Agilent Technologies' reportable segments resulting from a new organizational structure announced in November 2014. This aims to clarify how the company's operations will be reported moving forward.
Agilent Technologies is consolidating into three new segments: 1) Life Sciences and Applied Markets (combining life sciences excluding nucleic acid solutions, and chemical analysis), 2) Diagnostics and Genomics (merging diagnostics and genomics with nucleic acid solutions), and 3) Agilent CrossLab (formed from services and consumables).
No, the information provided in this Current Report on Form 8-K, specifically the segment information in Exhibit 99.1, is being furnished and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. This means Agilent is not subject to the liabilities of Section 18 for this furnished information.
The restructuring is designed to better serve Agilent's customers by creating more focused business segments. This enhanced focus is expected to improve operational efficiency, strategic clarity, and potentially drive better performance within each of the core market areas: life sciences and applied markets, diagnostics and genomics, and services/consumables.